ERES eResearch Technology Inc. featured news, full reports, and detailed charts
eResearch Technology Inc. (ERES) Wrap Up:
eResearchTechnology, Inc. (eRT), a Delaware corporation, was founded in 1977 to provide Cardiac Safety services to evaluate the safety of new drugs. eRT and its consolidated subsidiaries collectively are referred to as the “Company” or “we.” We provide technology and services that enable the pharmaceutical, biotechnology and medical device industries to collect, interpret and distribute cardiac safety and clinical data more efficiently. We are a market leader in providing centralized electrocardiographic services (Cardiac Safety services or EXPeRT® ECG services) and a leading provider of technology and services that streamline the clinical trials process by enabling our clients to evolve from traditional, paper-based methods to electronic processing using our EXPeRT® eClinical and EXPeRT® ePRO products and services. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f03%2f07%2f0000893220-08-000656.html#FIS_BUSINESS"www.ert.com
394 Employees
Founded in 1977
eResearchTechnology, Inc. (ERES:NASDAQ)
LAST $5.80 USD
CHANGE TODAY -0.10 -1.69%
VOLUME 522.4K
As of 4:00 PM 11/20/09 All times are local (Market data by Reuters is delayed by at least 15 minutes).
Snapshot of eResearchTechnology, Inc. (ERES)
|
OPEN
$5.85
|
PREVIOUS CLOSE
$5.90
|
|
|
DAY HIGH
$5.95
|
DAY LOW
$5.78
|
|
|
52 WEEK HIGH
10/30/09 - $8.50
|
52 WEEK LOW
11/21/08 - $3.86
|
|
|
MARKET CAP
281.1M
|
AVERAGE VOLUME 3 mo
325.6K
|
|
|
DILUTED EPS TTM
$0.26
|
SHARES OUTSTANDING
48.5M
|
|
|
ERES Does Not Pay Dividends
|
P/E TTM
22.4x
|
|
| K = Thousands M = Millions B = Billions | ||
ERES Top Compensated Officers
Dr. Michael J. McKelvey Ph.D.
Chief Executive Officer, President and Direct...
Age: 56
Total Annual Compensation: $500.0K
Mr. Keith D. Schneck
Chief Financial Officer, Principal Accounting...
Age: 53
Total Annual Compensation: $117.1K
Dr. Jeffrey S. Litwin M.D.
Chief Medical Officer and Executive Vice Pres...
Age: 51
Total Annual Compensation: $273.0K
Ms. Amy Furlong
Executive Vice President of Cardiac Safety
Age: 36
Total Annual Compensation: $242.0K
Mr. Robert S. Brown CPA
Senior Vice President of Strategic Marketing ...
Age: 53
Total Annual Compensation: $235.0K
Executives, Board Directors
Compensation as of Fiscal Year 2008.
Key developments for eResearchTechnology, Inc. (ERES)
eResearchTechnology, Inc. expected to Report Fiscal Year 2009 Results on February 22, 2010. This event was calculated by Capital IQ (Created on November 3, 2009).
11/3/2009
eResearchTechnology, Inc. expected to Report Fiscal Year 2009 Results on February 22, 2010. This event was calculated by Capital IQ (Created on November 3, 2009).
eResearchTechnology Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Month Period Ended September 30, 2009; Revised Guidance for the Fourth Quarter and Full Year of 2009
10/29/2009
eResearchTechnology Inc. reported unaudited consolidated earnings results for the third quarter and nine month period ended September 30, 2009. Net income was $2.8 million, or $0.06 per diluted share in the third quarter of 2009 compared to $6.9 million, or $0.13 per diluted share a year ago. Revenue was $22.7 million for the third quarter of 2009 compared to $33.9 million a year ago. The current year third quarter results do not include the EDC operations, which were sold on June 23, 2009. Operating income was $4.7 million and income before income taxes was $4.6 million against operating income was $10.5 million and income before income taxes was $10.8 million for the same period a year ago. Net income was $7.4 million, or $0.15 per diluted share, for the nine months ended September 30, 2009 compared to net income of $19.3 million, or $0.37 per diluted share, for the nine months ended September 30, 2008. Net revenues were $70.7 million for the nine months ended September 30, 2009 compared to $103.1 million for the nine months ended September 30, 2008. Operating income was $12.9 million and income before income taxes was $12.5 million against operating income was $29.8 million and income before income taxes was $30.7 million for the same period a year ago. Net cash provided by operating activities of $24.7 million against $26.8 million for the same period a year ago. The company invested in purchases of property and equipment of $3.6 million against $7.0 million for the same period a year ago. The Company revised guidance for the fourth quarter and full year of 2009. For the fourth quarter of 2009, management anticipates diluted net income per share of between $0.05 and $0.06. Management anticipates net revenues of between $22.0 million and $23.0 million for the fourth quarter of 2009 The company expects diluted net income per share for the full year 2009 of between $0.20 and $0.21. This is in line with the lower end of previously issued guidance. Due to the lower than anticipated level of Thorough QT bookings in the third quarter of 2009 and some delays in starts of Thorough QT studies, management anticipates net revenues Of between $92.7 million and $93.7 million.
eResearchTechnology, Inc., Q3 2009 Earnings Call, Oct-29-2009
10/21/2009
eResearchTechnology, Inc., Q3 2009 Earnings Call, Oct 29 2009
ERES Competitors
| Company | Last | Change |
| Biotel Inc | $2.40 USD | -0.20 |
| DataTrak International Inc | $0.37 USD | +0.04 |
| Medidata Solutions Inc | $16.68 USD | -1.10 |
| Merge Healthcare Inc | $3.07 USD | -0.07 |
| Phase Forward Inc | $15.81 USD | -0.09 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | ERES | Industry Range |
| Price/Earnings | 22.2x |
|
| Price/Sales | 2.8x |
|
| Price/Book | 2.1x |
|
| Price/Cash Flow | 21.5x |
|
| TEV/Sales | 2.1x |
|
|
ERES |
||
|
ERES transactions
| Type Date |
Target |
|
Merger/Acquisition
June 23, 2009 |
eResearchTechnology, Inc., Electronic Data Capture Business |
More Recent News About eResearch Technology Inc.
More news for ERES
ERT to Present at UBS Global Life Sciences Conference on September 21, 2009
PHILADELPHIA, Sept. 14 /PRNewswire-FirstCall/ -- ERT (Nasdaq: ERES - News), announced today that Dr. Michael J. McKelvey, the Company's President and CEO, and Keith Schneck, the Company's Executive Vice President and CFO, are scheduled to present at UBS Global Life Sciences Conference at 11:00 AM EDT on September 21, 2009 in New York City, New York. Interested parties may access the presentation by visiting the Company's corporate website at http://www.ert.com. The webcast may also be accessed at http://cc.talkpoint.com/ubsx001/092109a_ke/?entity=19_41WMLT4. The webcast will be available via replay for 90 days.About ERTBased in Philadelphia, PA, ERT (eResearchTechnology, Inc.) (www.ert.com) is a leading provider of centralized ECG, ePRO, and other services to the biopharmaceutical, medical device, and related industries. ERT products and services are enabled by EXPERT®, the Com...Click here to read the whole Article (external link)
ERT to Announce 2009 Third Quarter Results on October 29, 2009
PHILADELPHIA, Oct. 21 /PRNewswire-FirstCall/ -- ERT (Nasdaq: ERES - News), a leading provider of centralized ECG, ePRO, eClinical technology, and other services to the biopharmaceutical, medical device, and related industries, announced today that it will release its results for the 2009 third quarter on Thursday, October 29, 2009 after the market closes. After the release, the Company will host a conference call at 5:00 PM EDT that day. For the conference call, interested participants should dial 1-800-860-2442 when calling within the United States or 1-412-858-4600 when calling internationally. There will be a playback available as well. To listen to the playback, please call 1-877-344-7529 when calling within the United States or 1-412-317-0088 when calling internationally.This call is being webcast by MultiVu and can be accessed at ERT's website at www.ert.com. The webcast may also be accessed via the direct link at http://www.videonewswire.com/event.asp?id=63252. The webcast can be accessed for up to one year on either site.Based in Philadelphia, PA, eResearchTechnology, Inc. (...Click here to read the whole Article (external link)
Streetwalker: Five Stock Prospects Under $10
Home Business Tech Markets Entrepreneurs Leadership Personal Finance ForbesLife Lists Opinions Video Blogs E-mail Newsletters People Tracker Portfolio Tracker Special Reports Commerce Energy Health Care Logistics Manufacturing Media Services Technology Wall Street Washington CIO Network Enterprise Tech Infoimaging Internet Infrastructure Internet Personal Tech Sciences Security ...Click here to read the whole Article (external link)
Q3 2009 eResearch Technology Earnings Release - After Market Close
Earnings Announcements for Thursday, October 29CompanySymbolTimeConferenceCall3PAR Inc.PARAfter Market CloseListenABBABB01:00 am ETABG SUN COL HLDGASC.OLTime Not SuppliedAccuray IncorporatedARAYAfter Market CloseListenACHENG RELAY000922.SZTime Not SuppliedAcme Packet, Inc.APKTAfter Market CloseListenAcme UnitedACU09:00 am ETListenACS, Actividades de Construcción y Servicios, S.A.ACS.MCAfter Market CloseACTELIOSACT.MI10:00 am ETActuate CorporationACTUAfter Market CloseListenAdaptec, Inc.ADPTTime Not SuppliedListenAdolor CorporationADLRTime Not SuppliedListenADVA Optical NetworkingADV.FTime Not SuppliedListenAetna Inc.AETBefore Market OpenListenAGL ResourcesAGLBefore Market OpenListenAgree Realty...Click here to read the whole Article (external link)
ERT Reports Third Quarter 2009 Results
PHILADELPHIA, Oct. 29 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (ERT), (Nasdaq: ERES - News), a leading provider of centralized ECG, ePRO and other services to the biopharmaceutical, medical device and related industries, announced today results for the third quarter and nine-month period ended September 30, 2009. Unless otherwise noted, all comparative numbers refer to changes from the same period a year ago. Financial highlights for the third quarter of 2009: Financial highlights for the first nine months of 2009:"The quarter was marked by growth in our routine (Phase I - IV) business, offset by a continued weakness in our Thorough QT business," commented Dr. Michael McKelvey, President and CEO of ERT. "We recorded a book to bill ratio of 1.9 in the quarter, the highest that ERT has ever recorded in recent history. This was due to a strong increase in routine bookings, which increased 23% sequentially and 15% compared to the third quarter a year ago. Thorough QT bookings continued to be impacted by the delays in the timing of sponsors' decisions on starting these trials. Sponsors may delay the running of Thorough QT trials until later in the drug development cycle, though regulatory guidance ultimately requires that they be performed. The quarter also saw a pick up in new bookings for our emerging ePRO business. We increased our operating income margin to 20.7% sequentially despite flat revenue (excluding the divestiture of our EDC operations) and slightly lower pricing."...Click here to read the whole Article (external link)
CEO Interview: BioClinica, Inc. - Mark L. Weinstein
67 WALL STREET, New York - November 2, 2009 - The Wall Street Transcript has just published its Pharmaceuticals Report offering a timely review of the sector to serious investors and industry executives. This 76-page feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online. Topics covered: Small-Cap Specialty Pharma - Patent Expiration - Pending Health Care Reform - Cultivating And Expanding R&D Pipelines - Chinese Drug Manufacturers - Brisk M&A Activity - Indian Pharma VS. U.S. Pharma - Competition From Generics - FDA Approval Process - Clinical Research Outsourcing Market - Stem Cell-Based Technology - Cancer Radiation Therapy - Expansion Into Asian Markets - Traditional Chinese Medicine VS. Western Medicine In Chinese Pharma Companies include: Aeolus Pharmaceuticals (AOLS.OB); Nutra Pharma (NPHC.OB); Quick-Med Technologies (QMDT.OB); Abbott Labs (ABT); Alexza Pharmaceuticals (ALXA); AmexDrug Corporation (AXRX.OB); Aurobindo Pharma (AUROBINDOP.BO); BioClinica (BIOC); BioPharm Asia (BFAR.OB); Biocon (BIOCON.BO); Cephalon (CEPH); China Sky One Medical, Inc. (CSKI); Claris Lifesciences (CLARICH.BO); Cortex Pharmaceuticals (COR); Daiichi Sankyo (DSKYF.PK); Dr.Reddy's (RDY); Elan (Elan); Eli Lilly (LLY); Forest (FRX); GeoPharma (GORX); Glaxo (GSK); Glenmark (GLENMARK.BO); Johnson & Johnson (JNJ); Lupin (LUPINSL.BO); Mannatech (MTEX); Matrix Laboratories (ATRIXLAB.BO); Medical Nutrition (MDNU); Merck KGaA (MKGAY.PK); Mylan (MYL); Ne...Click here to read the whole Article (external link)
ERESEARCHTECHNOLOGY INC /DE/ Files SEC form 8-K, Results of Operations and Financial Condition
Show all filings for ERESEARCHTECHNOLOGY INC /DE/ | Request a Trial to NEW EDGAR Online Pro Form 8-K for ERESEARCHTECHNOLOGY INC /DE/ 29-Oct-2009Results of Operations and Financial Condition Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for in...Click here to read the whole Article (external link)
ERESEARCHTECHNOLOGY INC /DE/ Financials
PERIOD ENDING30-Sep-0930-Jun-0931-Mar-0931-Dec-08Total Revenue22,726 24,176 23,786 30,065 Cost of Revenue10,995 11,538 11,794 12,835 Gross Profit11,731 12,638 11,992 17,230 Operating ExpensesResearch Development989 993 1,149 1,171 Selling General and Administrative6,033 6,801 7,503 7,467 Non Recurring - - - - Others - - - - Total Operating Expenses - - - - Operating Income or Loss4,709 4,844 3,340 8,592 Income from Continuing OperationsTotal Other Income/Expenses Net(82)(409)116 808 Earnings Before Interest And Taxes4,627 4,435 3,456 9,400 Interest Expense - - - - Income Before Tax4,627 4,435 3,456 9,400 Income Tax Expense1,808 1,887 1,386 3,734 Minority Interest - - - - Net Income From Continuing Ops2,819 2,548 2,070 5,666 Non-recurring EventsDiscontinued Operations - - - - Extraordinary Items - - - - ...Click here to read the whole Article (external link)
ERESEARCHTECHNOLOGY INC /DE/ Files SEC form 10-Q, Quarterly Report
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations Cautionary Statement for Forward-Looking Information The following discussion and analysis should be read in conjunction with our consolidated financial statements and the related notes to the consolidated financial statements appearing elsewhere in this Form 10-Q. The following discussion and analysis includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect our current views as to future events and financial performance with respect to our operations. These statements can be identified by the fact that they do not relate strictly to historical or current facts. They use words such as "aim," "anticipate," "are confident," "estimate," "expect," "will be," "will continue," "will likely result," "project," "intend," "plan," "believe," "look to" and other words and terms of similar meaning in conjunction with a discussion of future operating or financial performance. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements. Factors that might cause such a difference include: unfavorable economic conditions; our ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects and internal issues at the sponsoring client; our ability to successfully integrate acquisitions; competitive factors in the market for centralized Cardiac Safety services; changes in the pharmaceutical, biotechnology and medical device industries to which we sell our solutions; technological development; and market demand. There is no guarantee that the amounts in our backlog will ever convert to revenue. Should the current economic condition...Click here to read the whole Article (external link)
Chairman Buys $6.4M Worth of Shaw Group
Stock quotes in this article: SHAW , MSFT , GOOG , ...Click here to read the whole Article (external link)
Would you like to leave a comment about eResearch Technology Inc. ERES
Find out what social network information about eResearch Technology Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides eResearch Technology Inc. there is more great information available at Realpennies.com